Bioxytran Inc   (BIXT)
Other Ticker:  
Price: $0.1175 $0.00 -0.424%
Day's High: $0.12 Week Perf: 0.43 %
Day's Low: $ 0.12 30 Day Perf: -10.51 %
Volume (M): 54 52 Wk High: $ 1.05
Volume (M$): $ 6 52 Wk Avg: $0.23
Open: $0.12 52 Wk Low: $0.07

 Market Capitalization (Millions $) 16
 Shares Outstanding (Millions) 136
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Bioxytran Inc
Bioxytran Inc is a biomedical technology company that specializes in the development of innovative therapeutic solutions for oxygen transport. The primary focus of the company is to create therapies that enhance oxygen delivery to tissues and organs in order to improve patient outcomes. The company utilizes its proprietary technology platform to develop and commercialize various oxygen-based therapeutics. These therapeutics have the potential to be used in the treatment of a wide range of medical conditions, including stroke, heart attacks, and other oxygen deprivation-related diseases. Bioxytran Inc aims to revolutionize the field of oxygen therapeutics by providing effective and safe treatments that address unmet medical needs.

   Company Address: 75 2nd Avenue Needham 2494 MA
   Company Phone Number: 454-1199   Stock Exchange / Ticker: BIXT
   BIXT is expected to report next financial results on March 30, 2024.

Customers Net Income grew by BIXT's Customers Net Profit Margin grew to

21.09 %

-27.27 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
NB        6.97% 
• View Complete Report

Bioxytran Inc

Bioxytran Inc Faces Investor Concerns as Operating Deficit Grows in Q3 2023

Following the recent announcement of operating deficit for the third quarter of 2023, Bioxytran Inc, a major player in the pharmaceutical preparations industry, has captured investors' attention. The company's financial performance has raised questions about its ability to generate revenue in the near future.
For the third quarter of 2023, Bioxytran Inc reported an operating deficit of $-0.985464 million. This represents a worsening of the deficit compared to the same period in 2022, where it stood at $0.014225 million. However, the main concern for investors lies in the absence of any reported revenue during this time frame.

Bioxytran Inc

Bioxytran Inc Reveals Staggering Operating Shortfall of $-1.02168 Million, Signaling Critical Financial Struggles in Fiscal Year Ending June 30, 2023

In light of the second quarter of 2023 financial results, the Major Pharmaceutical Preparations sector is facing significant concerns as Bioxytran Inc struggles to generate revenue and continues to experience increasing losses. Shareholders and market analysts have grown increasingly skeptical about the company's ability to steer itself out of this dire situation, casting a bearish outlook on Bioxytran Inc's future prospects.
Lack of Revenue and Widening Deficit:
The absence of any reported revenue for the April to June 30, 2023 quarter is undoubtedly alarming for Bioxytran Inc investors and shareholders. As the company fails to deliver any meaningful revenue, concerns about its business strategy and operational efficiency begin to rise. This absence of revenue is coupled with a significant net deficit of $-1.412 million, an alarming increase from the $-0.634 million deficit reported in the second quarter of 2022.

Bioxytran Inc

Bioxytran Inc Delivers Promising Q1 Results, Sets New Path in Healthcare Industry

Investors of Bioxytran Inc have been anticipating their upcoming financial report for January to March 31, 2023, and while they may not have been expecting any significant changes in revenue, the operating shortfall has been closely monitored. During the same period, the Major Pharmaceutical Preparations company's operating shortfall was $-0.750242 million, significantly overshadowing the results from the previous year. However, it is important to note that these numbers are primarily reflective of the progress span.
The positive news is that the operating shortfall has decreased to $-0.818 million from $-1.078 million in the first quarter of 2021. This marks a significant improvement and puts the company on the path to becoming a successful bellwether in the healthcare sector. While there may not be any substantial shifts in revenue, this deficit reduction is a promising sign for investors.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com